Johnson & Johnson pays $2.2 billion upfront for Ollin Biosciences and its Vabysmo challenger OLN324, and the FDA approves Genentech's Wilserdly (giredestrant) for ESR1 mutated breast cancer. Also: Helus Pharma's Phase 3 depression win, Lilly's purchase of Calytrix Bio, Seawolf's Sanofi pact and Novartis' ADC deal with OBI Pharma.
Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Tuesday, November 17.
Today, Johnson and Johnson pays two point two billion dollars upfront for an eye drug built to take on Roche, and the FDA clears Genentech's oral breast cancer pill giredestrant.
We start with the biggest deal of the day. Johnson and Johnson is acquiring Ollin Biosciences, according to BioPharm International and Fierce Biotech. The upfront price is two point two billion dollars, with up to about one point one billion more in regulatory and commercial milestones. The prize is OLN324, a compact bispecific antibody that blocks both VEGF and Ang2, licensed from Innovent, for wet age related macular degeneration and diabetic macular edema. That is the same dual mechanism behind Roche's Vabysmo, faricimab. In a Phase one b study called JADE, eighty two percent of patients on OLN324 went twelve weeks without retreatment, against eighty one percent on faricimab. Blackstone Life Sciences will put seven hundred fifty million dollars toward the Phase three program in return for milestones and royalties. Closing is expected before year end. For retina specialists, the real contest will be dosing intervals.
Next, a regulatory win in breast cancer. The FDA has approved Wilserdly, giredestrant, from Roche's Genentech unit, in combination with everolimus, as reported by CancerNetwork. It covers ER positive, HER2 negative advanced breast cancer with an ESR1 mutation after prior endocrine therapy, with the FoundationOne Liquid CDx blood test used to find eligible patients. In the Phase three evERA trial, median progression free survival in the ESR1 mutated group reached ten months, compared with five and a half months on standard endocrine therapy plus everolimus. Overall survival data are still immature. Giredestrant is an oral estrogen receptor degrader, and this approval gives Roche an oral option for patients whose tumors carry the ESR1 mutation.
In psychiatry, Helus Pharma reported a Phase three win for HLP003, a modified form of psilocin, as an add on treatment for major depression. In the APPROACH study of two hundred twenty two adults, depression scores at week six fell seven point six points more on HLP003 than on placebo, and the gap was already visible on day two. Remission at week six reached about fifty one percent, against eighteen percent on placebo. The company reported three serious adverse events judged related to treatment and no new safety signals. A second pivotal study, EMBRACE, reads out in the fourth quarter of twenty twenty seven. With Compass Pathways already filed, psychedelic medicine is moving from niche to late stage pipeline.
Eli Lilly is buying again. BioPharma Dive reports Lilly will pay up to one point five billion dollars for Calytrix Bio, a young Massachusetts company working on myelofibrosis and essential thrombocythemia. Calytrix has a biparatopic antibody, meaning it grips two sites on the same protein, aimed at a surface marker found in disease driven by CALR mutations. Calytrix argues that current options, such as Incyte's Jakafi, mostly manage symptoms. This is Lilly's fifteenth announced company acquisition this year, with more than thirty billion dollars spent, most of it on private startups. No other drugmaker has been as active in deals this year.
Two platform deals round out the day. Seawolf Therapeutics came out of stealth with one hundred million dollars in seed and Series A money and a Sanofi pact worth up to one point two billion dollars in milestones, according to Fierce Biotech and BioPharm International. Its TRIDENT platform packs DNA, rather than RNA, into lipid nanoparticles, with the aim of longer protein expression and repeat dosing that viral gene therapy struggles to offer. Sanofi's first targets are bleeding disorders. Investors include Versant Ventures, the Novartis Venture Fund, Lilly and CRISPR Therapeutics.
Meanwhile, Novartis signed a licensing deal with Taiwan's OBI Pharma for its glycan based conjugation technology, which links drug payloads to antibodies through their sugar chains, including a version that carries two payloads at once. Novartis pays thirty million dollars upfront, with a total potential value above two billion dollars plus royalties. The bet is that the next gains in antibody drug conjugates will come from new payloads and smarter attachment chemistry.
The thread running through today is that big pharma is buying the next generation of proven ideas, from a better shot for the eye to new ways of delivering genes and payloads, and in the case of Johnson and Johnson, sharing the cost with a financial partner.
That's the briefing for today. Pharma and Biotech Daily is produced by OWITH.ai. See you tomorrow.
Sources:
https://www.biopharminternational.com/view/deals-roundup-j-j-buys-ollin-lilly-adds-calytrix-and-novartis-and-sanofi-strike-platform-pacts
https://www.fiercebiotech.com/biotech/jj-pays-22b-upfront-ollin-challenge-roches-vabysmo
https://www.cancernetwork.com/view/fda-approves-giredestrant-everolimus-for-er-her2-esr1-mutated-breast-cancer
https://www.manilatimes.net/2026/11/16/tmt-newswire/globenewswire/helus-pharma-announces-positive-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder/2470802
https://www.biopharmadive.com/news/lilly-calytrix-bio-acquire-deal-myelofibrosis-essential-thrombocythemiaenial-/874719/
https://fiercebiotech.com/biotech/lilly-secures-another-myelofibrosis-option-15b-deal-jpm-founded-calytrix
https://www.fiercebiotech.com/biotech/dna-delivery-biotech-seawolf-surfaces-alongside-investors-novartis-lilly-and-partner-sanofi
https://biospace.com/press-releases/obi-pharma-signs-collaboration-and-license-agreement-with-novartis
Pharma and Biotech Daily is produced by OWITH.ai. Script and voice are AI generated from the public sources listed above. Not medical or investment advice.
Support the show